scholarly journals Clinical benefit of pulmonary hypertension using statin therapy: a population-based cohort study

2018 ◽  
Vol WCP2018 (0) ◽  
pp. PO4-5-17
Author(s):  
CHUNG-YU CHEN
Keyword(s):  
Pulmonary Hypertension ◽  
Cohort Study ◽  
Statin Therapy ◽  
Clinical Benefit ◽  
Population Based

scholarly journals Prevalence and determinants of pulmonary hypertension in the general population: results from a prospective population-based cohort study

2013 ◽  
Vol 34 (suppl 1) ◽  
pp. P917-P917
Author(s):  
E. Moreira ◽  
J. F. Felix ◽  
H. Tiede ◽  
M. J. G. Leening ◽  
D. W. Loth ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Cohort Study ◽  
General Population ◽  
Population Based

scholarly journals Effectiveness of Statins as Primary Prevention in People With Gout: A Population-Based Cohort Study

2019 ◽  
Vol 24 (6) ◽  
pp. 542-550
Author(s):  
Maria Garcia-Gil ◽  
Marc Comas-Cufí ◽  
Rafel Ramos ◽  
Ruth Martí ◽  
Lia Alves-Cabratosa ◽  
...  
Keyword(s):  
Primary Care ◽  
Cohort Study ◽  
Primary Prevention ◽  
Statin Therapy ◽  
Proportional Hazards ◽  
Population Based ◽  
Cox Proportional Hazards ◽  
Research Quality ◽  
All Cause Mortality ◽  
Clinically Significant

Background: Cardiovascular guidelines do not give firm recommendations on statin therapy in patients with gout because evidence is lacking. Aim: To analyze the effectiveness of statin therapy in primary prevention of coronary heart disease (CHD), ischemic stroke (IS), and all-cause mortality in a population with gout. Methods: A retrospective cohort study (July 2006 to December 2017) based on Information System for the Development of Research in Primary Care (SIDIAPQ), a research-quality database of electronic medical records, included primary care patients (aged 35-85 years) without previous cardiovascular disease (CVD). Participants were categorized as nonusers or new users of statins (defined as receiving statins for the first time during the study period). Index date was first statin invoicing for new users and randomly assigned to nonusers. The groups were compared for the incidence of CHD, IS, and all-cause mortality, using Cox proportional hazards modeling adjusted for propensity score. Results: Between July 2006 and December 2008, 8018 individuals were included; 736 (9.1%) were new users of statins. Median follow-up was 9.8 years. Crude incidence of CHD was 8.16 (95% confidence interval [CI]: 6.25-10.65) and 6.56 (95% CI: 5.85-7.36) events per 1000 person-years in new users and nonusers, respectively. Hazard ratios were 0.84 (95% CI: 0.60-1.19) for CHD, 0.68 (0.44-1.05) for IS, and 0.87 (0.67-1.12) for all-cause mortality. Hazard for diabetes was 1.27 (0.99-1.63). Conclusions: Statin therapy was not associated with a clinically significant decrease in CHD. Despite higher risk of CVD in gout populations compared to general population, patients with gout from a primary prevention population with a low-to-intermediate incidence of CHD should be evaluated according to their cardiovascular risk assessment, lifestyle recommendations, and preferences, in line with recent European League Against Rheumatism recommendations.

scholarly journals Risk of cardiovascular events and pulmonary hypertension following splenectomy — a Danish population-based cohort study from 1996–2012

Haematologica ◽  
2017 ◽  
Vol 102 (8) ◽  
pp. 1333-1341 ◽  
Author(s):  
Marianne Rørholt ◽  
Waleed Ghanima ◽  
Dora Körmendiné Farkas ◽  
Mette Nørgaard
Keyword(s):  
Pulmonary Hypertension ◽  
Cohort Study ◽  
Cardiovascular Events ◽  
Population Based ◽  
Danish Population

scholarly journals Incidence and risk factors of chronic thromboembolic pulmonary hypertension following venous thromboembolism, a population-based cohort study in England

2018 ◽  
Vol 8 (3) ◽  
pp. 204589401879135 ◽  
Author(s):  
C. Martinez ◽  
C. Wallenhorst ◽  
S. Teal ◽  
A.T. Cohen ◽  
A.J. Peacock
Keyword(s):  
Risk Factors ◽  
Pulmonary Embolism ◽  
Pulmonary Hypertension ◽  
Cohort Study ◽  
Venous Thromboembolism ◽  
Conditional Logistic Regression ◽  
Chronic Thromboembolic Pulmonary Hypertension ◽  
Population Based ◽  
Thromboembolic Pulmonary Hypertension

Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of unresolved organised pulmonary emboli/thrombi obstructing the major pulmonary arteries. The aim of this study was to estimate the incidence and risk factors of CTEPH in a cohort with first venous thromboembolism (VTE). This was a population-based cohort study of patients with first VTE and no active cancer in England between 2001 and 2012. CTEPH was assessed using a rigorous case-ascertainment algorithm. Risk factors for CTEPH were studied using a nested case-control approach by matching CTEPH cases to VTE patients without CTEPH. Adjusted odds ratios (OR) of comorbidities were estimated from conditional logistic regression. During 81,413 person-years of follow-up among 23,329 patients with first VTE (mean follow-up 3.5 years; maximum 11.0 years) 283 patients were diagnosed with CTEPH (incidence rate 3.5 per 1000 person-years); cumulative incidence was 1.3% and 3.3% at 2 and 10 years after pulmonary embolism, and 0.3% and 1.3% following deep vein thrombosis (DVT), respectively. Risk factors for CTEPH included age over 70, OR 2.04 (95% CI 1.23 to 3.38), female gender, 1.44 (1.06 to 1.94), pulmonary embolism at first VTE, 3.11 (2.23 to 4.35), subsequent pulmonary embolism and DVT, 3.17 (2.02 to 4.96) and 2.46 (1.34 to 4.51) respectively, chronic obstructive pulmonary disease 3.17 (2.13 to 4.73), heart failure 2.52 (1.76 to 3.63) and atrial fibrillation, 2.42 (1.71 to 3.42). CTEPH develops most commonly after pulmonary embolism and less frequently after DVT. Awareness of risk factors may increase referrals to specialised centres for confirmation of CTEPH and initiation of specific treatment.

Sign in / Sign up

Export Citation Format

Share Document